Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

<p>No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) —  Beyond Cancer, […]</p>
<p>The post <a href="https://forextv.com/top-news/beyond-cancer-phase-1-study-clears-cohort-1-in-patients-with-advanced-relapsed-or-refractory-unresectable-primary-or-metastatic-cutaneous-or-subcutaneous-solid-tumors/">Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>